Clarithromycin

Generic Name
Clarithromycin
Brand Names
Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500
Drug Type
Small Molecule
Chemical Formula
C38H69NO13
CAS Number
81103-11-9
Unique Ingredient Identifier
H1250JIK0A
Background

Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Indication

An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).

Clarithromycin is indicated in combination with vonoprazan and amoxicillin as co-packaged triple therapy to treat Helicobacter pylori (H. pylori) infection in adults.

Associated Conditions
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections
Associated Therapies
-

A Study to Evaluate the Effect of Clarithromycin on LY2216684

First Posted Date
2011-10-26
Last Posted Date
2018-10-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
14
Registration Number
NCT01460407
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

First Posted Date
2011-06-15
Last Posted Date
2018-12-10
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
14
Registration Number
NCT01374217
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-03-31
Last Posted Date
2011-03-31
Lead Sponsor
Zekai Tahir Burak Women's Health Research and Education Hospital
Target Recruit Count
273
Registration Number
NCT01326611
Locations
🇹🇷

Zekai Tahir Burak Maternity Teaching Hospital Neonatology department, Ankara, Turkey

Treatment of Mycobacterium Xenopi Pulmonary Infection

First Posted Date
2011-02-17
Last Posted Date
2020-07-20
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Target Recruit Count
92
Registration Number
NCT01298336
Locations
🇫🇷

CH Béthune, Béthune, France

🇫🇷

CHU Besançon, Besançon, France

🇫🇷

CH Abbeville, Abbeville, France

and more 49 locations

Clarithromycin as Immunomodulator for the Management of Sepsis

First Posted Date
2010-10-19
Last Posted Date
2011-08-04
Lead Sponsor
University of Athens
Target Recruit Count
600
Registration Number
NCT01223690
Locations
🇬🇷

2nd Department of Surgery, University of Thessaloniki, Thessaloniki, Greece

🇬🇷

2nd Department of Medicine, Sismanogleion General Hospital, Athens, Greece

🇬🇷

4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

and more 3 locations

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

First Posted Date
2010-07-09
Last Posted Date
2019-06-11
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
121
Registration Number
NCT01159574
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

Drug-Drug Interaction Study of Colchicine and Clarithromycin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-09-24
Last Posted Date
2009-10-15
Lead Sponsor
Mutual Pharmaceutical Company, Inc.
Target Recruit Count
24
Registration Number
NCT00984061
Locations
🇺🇸

PRACS Institute, Ltd. - Cetero Research, Fargo, North Dakota, United States

Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-02-04
Last Posted Date
2024-08-20
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
24
Registration Number
NCT00836706
Locations
🇺🇸

PRACS Institute, Ltd., East Grand Forks, Minnesota, United States

Clarithromycin 500 mg Tablets Under Fasting Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-02-04
Last Posted Date
2024-08-20
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
60
Registration Number
NCT00835692
Locations
🇺🇸

PRACS Institute Ltd, Fargo, North Dakota, United States

© Copyright 2024. All Rights Reserved by MedPath